Related Experiment Video
Updated: Apr 30, 2026
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Renal cell carcinoma: how to hit the targets?
Oleg Banyra1, Marjan Tarchynets2, Alexander Shulyak3
12nd Lviv Municipal Polyclinic, Lviv, Ukraine.
Introduction:
Renal cell carcinoma (RCC) is a widespread oncourological disease with a tendency towards a slow increase of incidence. In the recent decade, there has been development of numerous effective drugs targeted at different molecules that play a dominant role in RCC carcinogenesis. Understanding of RCC carcinogenesis confirms the key role of angiogenesis in maintaining the viability of renal tumours and their metastases.
Material And Methods:
We aimed to systemize numerous medicines, used to inhibit the angiogenesis in patients with advanced RCC according to their targets, and to analyze their efficacy.
Results:
There are roughly four main mechanisms of action of the targeted drugs:Blockade of circulating extracellular VEGF molecules.The selective blockade of tyrosine kinase receptors' domains.The simultaneous blockage of the tyrosine kinase receptors' domains and intracellular tyrosine kinases.The blockade of mammalian target of rapamycin (mTOR) which is responsible for support of vital functions of cancer cells. In addition to FDA officially approved drugs, numerous experimental agents have been synthesized, which are currently on initial stages of clinical studies in RCC treatment.
Conclusions:
The results of the currently used targeted drugs demonstrate perspectives of metastatic RCC conservative treatment, that are able to prolong cancer-specific survival in previously doomed patients for up to 29 months. The development of schedules for sequential treatment or combination targeted therapy remains a current challenge. The quality of life is an important factor that influences remedy choice. The advantages and disadvantages of neoadjuvant and adjuvant targeted therapy are currently being intensively discussed.
Insights
Targeted therapies inhibiting angiogenesis offer new hope for advanced renal cell carcinoma (RCC), prolonging survival by up to 29 months. Further research is needed for optimal sequential or combination treatment strategies.
Area of Science:
- Oncourology
- Medical Oncology
- Translational Research
Background:
- Renal cell carcinoma (RCC) incidence is increasing globally.
- Targeted therapies have emerged, focusing on key molecules in RCC development.
- Angiogenesis is critical for renal tumor and metastasis survival.
Purpose of the Study:
- To categorize anti-angiogenic drugs for advanced RCC by their molecular targets.
- To evaluate the efficacy of these targeted angiogenesis inhibitors.
Main Methods:
- Systematic review of targeted therapies for advanced RCC.
- Classification of drugs based on their mechanism of action.
- Analysis of clinical efficacy data.
Main Results:
- Four primary mechanisms of action identified: VEGF blockade, tyrosine kinase receptor inhibition (selective or simultaneous), and mTOR pathway inhibition.
- FDA-approved drugs and experimental agents are in clinical development.
- Targeted therapies demonstrate significant survival benefits.
Conclusions:
- Targeted angiogenesis inhibitors offer promising conservative treatment for metastatic RCC.
- These therapies can extend cancer-specific survival by up to 29 months.
- Optimizing sequential/combination therapy and considering quality of life are key future challenges.
